Ondine Biomedical Inc. announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.72 GBX | +6.48% | -6.42% | -11.77% |
Jun. 10 | Transcript : Ondine Biomedical Inc., 2023 Earnings Call, Jun 10, 2024 | |
Jun. 07 | Ondine Biomedical loss narrows as revenue soars 88% in 2023 | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.77% | 25.58M | |
-3.64% | 187B | |
-0.15% | 109B | |
-2.46% | 69.22B | |
-6.05% | 46.36B | |
+13.48% | 46.19B | |
+8.48% | 42.44B | |
+17.99% | 30.84B | |
+19.69% | 25.73B | |
-8.91% | 23.3B |
- Stock Market
- Equities
- OBI Stock
- News Ondine Biomedical Inc.
- Mater Hospital, to Use Ondine Biomedical's Award-Winning Light-Activated Antimicrobial Technology